Evidence map›Paper›PMID 27393705›Full record

ArticleAntioxidants & redox signaling2017

Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like Disease in Mice.

Jean Christopher Chamcheu, Vaqar M Adhami, Stephane Esnault, Mario Sechi, Imtiaz A Siddiqui, Kenneth A Satyshur, Deeba N Syed, Shah-Jahan M Dodwad, Maria-Ines Chaves-Rodriquez, B Jack Longley and 2 more

Abstract read
In one paragraph

Article in Antioxidants & redox signaling, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 93 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Ang-1 and VEGF: central regulators of angiogenesis.Molecular and cellular biochemistry · 2025
    Review
  9. Review
  10. mTORC1 and mTORC2 Levels in Patients with Psoriasis.Dermatology practical & conceptual · 2024
    Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Nutrients · 2022
    Article
  18. Unravelling Potential Health-Beneficial Properties ofPharmaceuticals (Basel, Switzerland) · 2022
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Jean Christopher Chamcheu1 Department of Dermatology, School of Medicine and Public Health, University of Wisconsin , Madison, Wisconsin.
Vaqar M Adhami1 Department of Dermatology, School of Medicine and Public Health, University of Wisconsin , Madison, Wisconsin.
Stephane Esnault2 Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, School of Medicine and Public Health, University of Wisconsin , Madison, Wisconsin.
Mario Sechi3 Department of Chemistry and Pharmacy, University of Sassari , Sassari, Italy .
Imtiaz A Siddiqui1 Department of Dermatology, School of Medicine and Public Health, University of Wisconsin , Madison, Wisconsin.
Kenneth A Satyshur4 Small Molecule Screening Facility, Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin , Madison, Wisconsin.
Deeba N Syed1 Department of Dermatology, School of Medicine and Public Health, University of Wisconsin , Madison, Wisconsin.
Shah-Jahan M Dodwad1 Department of Dermatology, School of Medicine and Public Health, University of Wisconsin , Madison, Wisconsin.
Maria-Ines Chaves-Rodriquez1 Department of Dermatology, School of Medicine and Public Health, University of Wisconsin , Madison, Wisconsin.
B Jack Longley1 Department of Dermatology, School of Medicine and Public Health, University of Wisconsin , Madison, Wisconsin.
Gary S Wood1 Department of Dermatology, School of Medicine and Public Health, University of Wisconsin , Madison, Wisconsin.
Hasan Mukhtar1 Department of Dermatology, School of Medicine and Public Health, University of Wisconsin , Madison, Wisconsin.
University of Wisconsin–Madison · USLebanon VA Medical Center · USUniversity of Sassari · IT

Funding

Targeting PI3K/Akt/mTOR for the management of psoriasisR01AR059742 · NIAMS · UNIVERSITY OF WISCONSIN-MADISON · PI MUKHTAR, HASAN · 2010 to 2019
$3.3M
NIAMS NIH HHS R01 AR059742
6 · The paper itself

Abstract

aimThe treatment of psoriasis remains elusive, underscoring the need for identifying novel disease targets and mechanism-based therapeutic approaches. We recently reported that the PI3K/Akt/mTOR pathway that is frequently deregulated in many malignancies is also clinically relevant for psoriasis. We also provided rationale for developing delphinidin (Del), a dietary antioxidant for the management of psoriasis. This study utilized high-throughput biophysical and biochemical approaches and in vitro and in vivo models to identify molecular targets regulated by Del in psoriasis.

resultsA kinome-level screen and Kds analyses against a panel of 102 human kinase targets showed that Del binds to three lipid (PIK3CG, PIK3C2B, and PIK3CA) and six serine/threonine (PIM1, PIM3, mTOR, S6K1, PLK2, and AURKB) kinases, five of which belong to the PI3K/Akt/mTOR pathway. Surface plasmon resonance and in silico molecular modeling corroborated Del's direct interactions with three PI3Ks (α/c2β/γ), mTOR, and p70S6K. Del treatment of interleukin-22 or TPA-stimulated normal human epidermal keratinocytes (NHEKs) significantly inhibited proliferation, activation of PI3K/Akt/mTOR components, and secretion of proinflammatory cytokines and chemokines. To establish the in vivo relevance of these findings, an imiquimod (IMQ)-induced Balb/c mouse psoriasis-like skin model was employed. Topical treatment of Del significantly decreased (i) hyperproliferation and epidermal thickness, (ii) skin infiltration by immune cells, (iii) psoriasis-related cytokines/chemokines, (iv) PI3K/Akt/mTOR pathway activation, and (v) increased differentiation when compared with controls. Innovation and Conclusion: Our observation that Del inhibits key kinases involved in psoriasis pathogenesis and alleviates IMQ-induced murine psoriasis-like disease suggests a novel PI3K/AKT/mTOR pathway modulator that could be developed to treat psoriasis. Antioxid. Redox Signal. 26, 49-69.

Indexed as

Phosphoinositide-3 Kinase InhibitorsAdministration, TopicalAminoquinolinesAnimalsAnthocyaninsAntioxidantsBinding SitesBiopsyChemotaxis, LeukocyteCytokinesDisease Models, AnimalImiquimodImmunomodulationInflammation MediatorsMiceModels, MolecularAminoquinolinesAnthocyaninsAntioxidantsCytokinesdelphinidinImiquimodInflammation MediatorsPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktRibosomal Protein S6 Kinases, 70-kDaTOR Serine-Threonine Kinasesantioxidantsdelphinidinimiquimod model of inflammationpsoriasis

Identifiers

PMID27393705
PMCPMC5206770
OpenAlexW2465174798

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.